Efectos clínicos y psicológicos postmanejo intralesional con Colagenasa Clostridium histolyticum en la enfermedad de Peyronie. Revisión bibliográfica

Christopher Acosta Núñez; Estefanía Aracelly Reyes Rosero

doi:10.56294/saludcyt2023419

Autores/as

Christopher Hilario Acosta Nuñez Universidad Técnica de Ambato, Facultad Ciencias de la Salud, Carrera de Medicina. Ambato, Ecuador https://orcid.org/0000-0002-3004-3381
Estefanía Aracelly Reyes Rosero Universidad Técnica de Ambato, Facultad Ciencias de la Salud, Carrera de Medicina. Ambato, Ecuador https://orcid.org/0000-0002-9931-5816

DOI:

https://doi.org/10.56294/saludcyt2023419

Palabras clave:

Clostridium histolyticum, inyecciones intralesionales, curvatura del pene, enfermedad de Peyronie

Resumen

Introducción: La enfermedad de Peyronie (EP) es un trastorno inflamatorio y fibrótico que afecta la túnica albugínea del pene que obedece a un enfoque multifactorial. Se caracteriza por la formación de una placa de tejido fibroso que produce una deformación angular en el pene que resulta en disfunción eréctil y problemas psicosexuales hacia el paciente. En el estudio de su tratamiento, la terapia intralesional fue una opción durante mucho tiempo sin resultados contundentes hasta la implementación de la colagenasa de clostridium histolyticum (CCH).
Objetivo: Describir los resultados clínicos y psicológicos obtenidos de la intervención intralesional con colagenasa de clostridium histolyticum en el tratamiento de la EP. Métodos: Realizar una búsqueda bibliográfica de información actualizada en la base de datos de Pubmed bajo términos como enfermedad de Peyronie, fibromatosis peneana, colagenasa clostridium histolyticum.
Resultados: Se obtuvieron 15 investigaciones desde el 2018 al 2023, con un total de 2.844 pacientes, en todos los estudios se reportaron mejorías en la corrección peneana, en 9 estudios reportaron resultados satisfactorios en IIEF-15 y PDQ, al igual que los resultados se vieron influidos por las características individuales, así como la modificación del protocolo terapéutico o agregación de terapias adyuvantes.
Conclusiones: La terapia intralesional con CCH ha demostrado ser eficaz con y sin el uso de terapias concomitantes en la corrección de la curvatura peneana y disminución de los síntomas psicosexuales en la EP desde el primer ciclo terapéutico al igual que en casos atípicos, etapa aguda y en pacientes que reportaron calcificación.

Métricas

Cargando métricas ...

Citas

Cocci A, Cito G, Urzì D, Minervini A, Di Maida F, Sessa F, et al. Sildenafil 25 mg ODT + Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie’s Disease: A Matched-Pair Comparison Analysis. The Journal of Sexual Medicine 2018;15:1472–7. https://doi.org/10.1016/J.JSXM.2018.08.012.

Kayes O, Babu A. Recent advances in managing Peyronie’s disease. F1000Research 2020;9. https://doi.org/10.12688/F1000RESEARCH.20557.1/DOI.

Trost L, Huang H, Han X, Burudpakdee C, Hu Y. Treatment Patterns and Healthcare Outcomes with Collagenase Clostridium Histolyticum vs Surgery in Peyronie’s Disease: A Retrospective Claims Database Analysis. Sexual Medicine 2021;9. https://doi.org/10.1016/J.ESXM.2021.100321.

Tsambarlis P, Levine LA. Nonsurgical management of Peyronie’s disease. Nature Reviews Urology 2019;16:172–86. https://doi.org/10.1038/S41585-018-0117-7.

Cocci A, Russo GI, Salonia A, Cito G, Regis F, Polloni G, et al. Predictive Factors of Patients’ and Their Partners’ Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie’s Disease: Results From a Multi-Center Single-Arm Study. The Journal of Sexual Medicine 2018;15:716–21. https://doi.org/10.1016/J.JSXM.2018.03.084.

Kadioglu A, Dincer M, Salabas E, Culha MG, Akdere H, Cilesiz NC. A Population-Based Study of Peyronie’s Disease in Turkey: Prevalence and Related Comorbidities. Sexual Medicine 2020;8:679–85. https://doi.org/10.1016/J.ESXM.2020.09.002.

Gianazza S, Belladelli F, Leni R, Masci F, Rossi P, Gianesini G, et al. Peyronie’s disease development and management in diabetic men. Andrology 2023;11:372–8. https://doi.org/10.1111/ANDR.13224.

Ziegelmann MJ, Bajic P, Levine LA. Peyronie’s disease: Contemporary evaluation and management. International Journal of Urology 2020;27:504–16. https://doi.org/10.1111/IJU.14230.

Yang CH, Lin DY, Lin YS, Hsu CY, Tung MC, Tan KT, et al. The Immunological Microenvironment and the Emerging Role of Stem Cells Therapy in Peyronie’s Disease: A Systematic Narrative Review. International Journal of Molecular Sciences 2023;24. https://doi.org/10.3390/IJMS24010777.

Hayat S, Brunckhorst O, Alnajjar HM, Cakir OO, Muneer A, Ahmed K. A systematic review of non-surgical management in Peyronie’s disease. International Journal of Impotence Research 2022. https://doi.org/10.1038/S41443-022-00633-W.

Cilio S, Fallara G, Capogrosso P, Candela L, Belladelli F, Pozzi E, et al. The symptomatic burden of Peyronie’s disease at presentation according to patient age: A critical analysis of the Peyronie’s disease questionnaire (PDQ) domains. Andrology 2023;11. https://doi.org/10.1111/ANDR.13352.

Chung E, Wang J. Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie’s Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates. Investigative and Clinical Urology 2022;63:563–8. https://doi.org/10.4111/ICU.20220145.

Li MK, Sigalos JT, Yoffe DA, Modiri N, Hu M-Y, Gaither TW, et al. Multiple courses of intralesional collagenase injections for Peyronie disease: a retrospective analysis. The Journal of Sexual Medicine 2023;20. https://doi.org/10.1093/JSXMED/QDAC030.

Ziegelmann M, Hu Y, Xiang Q, Liu G, McLane MP, Trost L. Incremental Treatment Response by Cycle With Collagenase Clostridium Histolyticum for Peyronie’s Disease: a Pooled Analysis of Two Phase 3 Trials. Urology 2023. https://doi.org/10.1016/J.UROLOGY.2023.02.019.

García-Gómez B, García-Rojo E, Alonso-Isa M, Medina-Polo J, Santos-Pérez de la Blanca R, Justo-Quintas J, et al. Treatment of peyronie’s disease with combination of clostridium histolyticum collagenase and penile traction therapy: a prospective, multicenter, single-arm study. International Journal of Impotence Research 2021;33:325–31. https://doi.org/10.1038/S41443-020-0292-Y.

Geelhoed JP, Wegelin O, Tromp E, de Boer B, de Jong I, Beck JJH. Improvement in the ability to have sex in patients with Peyronie’s disease treated with Collagenase Clostridium histolyticum. BJUI Compass 2022;4:66–73. https://doi.org/10.1002/BCO2.185.

Flores A, Tyler A, Green B, Price T, Savage J, Brearton K, et al. Improved Peyronie’s Disease Curvature Outcomes Using a Novel Collagenase Administration Protocol. Urology 2022;170:117–23. https://doi.org/10.1016/j.urology.2022.09.017.

Melgarejo-Segura MT, Funes-Padilla C, Morales-Martínez A, López-Carmona-Pintado F, Arrabal-Martín M. Safety and Efficacy Study of Collagenase Clostridium Histolyticum Applied With an Intensive Protocol in the Treatment of Peyronie’s Disease. Sexual Medicine 2021;9. https://doi.org/10.1016/J.ESXM.2021.100375.

Flores JM, Nascimento B, Punjani N, Salter CA, Bernie HL, Taniguchi H, et al. Predictors of Curvature Improvement in Men With Peyronie’s Disease Treated With Intralesional Collagenase Clostridium Histolyticum. The Journal of Sexual Medicine 2022;19:1680–6. https://doi.org/10.1016/J.JSXM.2022.08.001.

Alom M, Burgon H, Ziegelmann M, Köhler T, Helo S, Trost L. Continuing Collagenase Clostridium Histolyticum Injections Among Initial Nonresponders Results in Significant Curvature Improvements in the Majority of Peyronie’s Disease Men. The Journal of Sexual Medicine 2021;18:1092–8. https://doi.org/10.1016/J.JSXM.2021.03.075.

Masterson TA, Atuluru P, Zucker I, Molina M, Ibrahim E, Nackeeran S, et al. Collagenase Clostridium histolyticum Treatment Improves Degree of Curvature in Peyronie’s Disease with Calcified Plaques. European Urology Focus 2023;9. https://doi.org/10.1016/J.EUF.2022.09.019.

Hu MYY, Sigalos JT, Walker DT, Li MK, Yoffe DA, Modiri N, et al. Intralesional collagenase Clostridium histolyticum for acute phase Peyronie’s disease: a single-center, retrospective cohort study. Translational Andrology and Urology 2022;11:1074–82. https://doi.org/10.21037/TAU-22-188/COIF).

Flores JM, Salter CA, Nascimento B, Terrier JE, Taniguchi H, Bernie HL, et al. The Prevalence and Predictors of Penile Pain in Men with Peyronie’s Disease. Sexual Medicine 2021;9. https://doi.org/10.1016/J.ESXM.2021.100398.

Cocci A, Di Maida F, Russo GI, Capogrosso P, Francesco L, Rizzo M, et al. Efficacy of Collagenase Clostridium histolyticum (Xiapex®) in Patients with the Acute Phase of Peyronie’s Disease. Clinical Drug Investigation 2020;40:583–8. https://doi.org/10.1007/S40261-020-00916-4.

El-Khatib FM, Osman MM, Kopelevich A, Towe M, Yafi FA. Treatment-related Outcomes for Patients With Atypical Peyronie’s Disease Using Xiaflex Injections. Urology 2020;143:153–8. https://doi.org/10.1016/J.UROLOGY.2020.05.076.

Carson C. Peyronie’s disease: new paradigm for the treatment of a unique cause of erectile dysfunction. Postgraduate Medicine 2020;132:4–8. https://doi.org/10.1080/00325481.2020.1805865.

Li E V., Esterquest R, Pham MN, Panken EJ, Amarasekera C, Siebert A, et al. Peyronie’s disease: pharmacological treatments and limitations. Expert Review of Clinical Pharmacology 2021;14:703–13. https://doi.org/10.1080/17512433.2021.1903873.

Krieger JR, Rizk PJ, Kohn TP, Pastuszak A. Shockwave Therapy in the Treatment of Peyronie’s Disease. Sexual Medicine Reviews 2019;7:499–507. https://doi.org/10.1016/J.SXMR.2019.02.001.

Walton EL, Quinn TP, Mulloy E, Patil D, Mehta A. Cost of Intralesional Collagenase Clostridium Histiolyticum Therapy Versus Surgery for the Management of Peyronie’s Disease: A Claims-Based Analysis (2009-2019). Sexual Medicine 2022;10. https://doi.org/10.1016/J.ESXM.2022.100517.